Table 1.

Synergy parameters of AZD2014 and Dasatinib applied together at equimolar concentrations to primary VS cells and S3 NF2-null SC-CRISPR cells.

Cells	AZD2014+ Dasatinib (µM)	Fractional inhibition (Fa)	CI	Description	DRI (AZD2014)	DRI (Dasatinib)
Primary VS cells	0.001 + 0.001	0.161	1.272	Moderate antagonism	4.798	0.941
	0.01 + 0.01	0.425	0.082	Very strong synergism	33.542	18.990
	0.1 + 0.1	0.705	0.013	Very strong synergism	135.233	192.714
	1 + 1	0.770	0.039	Very strong synergism	39.297	73.091
	10 + 10	0.750	0.565	Synergism	2.803	4.793
S3 NF2-null SC-CRISPR cells	0.002 + 0.002	0.010*	2.385	Antagonism	2.551	0.502
	0.014 + 0.014	0.082	0.424	Synergism	7.584	3.421
	0.123 + 0.123	0.425	0.120	Strong Synergism	16.518	16.698
	1.111 + 1.111	0.780	0.095	Very strong synergism	16.301	29.971
	10 + 10	0.828	0.537	Synergism	2.765	5.707

Combination index (CI) and dose- reduction index (DRI) were calculated from CI- and DRI- equation algorithms using CompuSyn software (Chou-Talalay CI method)³⁰. CI < 1, C = 1, and C > 1 indicate synergism, additive effect, and antagonism, respectively. DRI < 1, DRI = 1, and DRI > 1 indicate not favorable dose-reduction, no dose-reduction, and favorable dose-reduction, respectively. Fa- fraction affected (i.e. fractional inhibition of metabolic activity). *This is an approximation because the actual value was below 0.01, which is the lowest value allowed by the algorithm.